Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL3862996 | 0.82 | LMNA (0.57) | LMNAL3MBTL1CYP1A2GAAMAPT | |
| Tannin Pyrogallol SCHEMBL22288201 | 0.80 | LMNA (0.55) | LMNAL3MBTL1CHRNB2CHRNA4CYP1A2 | |
| Biphenyl SCHEMBL8087383 | 0.80 | LMNA (0.55) | LMNAL3MBTL1CYP1A2GAAMAPT | |
| Bromobenzene SCHEMBL2045059 | 0.78 | LMNA (0.52) | LMNAL3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7673402 | 0.78 | LMNA (0.52) | LMNAL3MBTL1SLC6A2SLC6A4SLC6A3 | |
| Benzenethiol SCHEMBL4312885 | 0.78 | LMNA (0.52) | LMNAL3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL449609 | 0.78 | LMNA (0.52) | LMNAL3MBTL1SLC6A2SLC6A4SLC6A3 | |
| Phenol SCHEMBL3315051 | 0.78 | LMNA (0.52) | LMNATSHRL3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL9821507 | 0.78 | LMNA (0.46) | LMNASLC6A2SLC6A4SLC6A3CHRNB2 | |
| O-Xylene SCHEMBL28066372 | 0.77 | LMNA (0.57) | LMNATSHRL3MBTL1SLC6A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424869-B1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| EP-2424869-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| CN-1172385-C | Positive electrode of charging battery and its manufacturing method | 佳能株式会社 | 2004-10-20 | — | — | CN | disclosed |
| CN-1079587-C | Rechargeable battery and method for manufacturing same | CANON KK (JP) | 2002-02-20 | — | — | CN | disclosed |
| CN-1305235-A | Positive electrode of charging battery and its manufacturing method | CANON KK (JP) | 2001-07-25 | — | — | CN | disclosed |
| US-6174884-B1 | CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-16 | — | — | US | disclosed |
| CN-1135097-A | Improved anode, rechargeable battery and method for manufacturing the anode | CANON KK (JP) | 1996-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | LMNA 4766/4885TSHR 536/4885L3MBTL1 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.